Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Jatoi, Ismail ^a,b   Bandos, Hanna ^c   Jeong, Jong Hyeon ^c   Anderson, William F ^d   Romond, Edward H ^a,e   Mamounas, Eleftherios P ^a,f   Wolmark, Norman ^a,g  

^a NSABP Foundation Inc   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f ORLANDO HEALTH   (United States)

^g ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; DATA BASE; DISEASE FREE SURVIVAL; DISTANT RECURRENCE; HUMAN; LOCAL REGIONAL RECURRENCE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC THERAPY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; FEMALE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREVENTION AND CONTROL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; TIME FACTOR; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961242376     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv304     Document Type: Article

References (37)

1. Jatoi I, Anderson WF, Jeong JH, et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29(17):2301-2304.
2. Cox DR. Regression Models and Life-Tables. J Royal Stat Soc. Series B (Methodol). 1972;34(2):187-220.
3. Jeong JH, Jung SH, Wieand S. A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med. 2003;22(3):339-352.
4. Demicheli R, Miceli R, Moliterni A, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005;16(9):1449-1457.
5. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658-1667.
6. Erratum in JAMA. 2006;295(20):2356.
7. Dignam JJ, Dukic V, Anderson SJ, et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009;116(3):595-602.
8. Fisher B, Fisher ER, Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986;4(6):929-941.
9. Fisher B, Redmond C, Wolmark N, et al. Disease-free survival at intervals during and following completion of adjuvant chemotherapy: The NSABP experience from three breast cancer protocols. Cancer. 1981;48(6):1273-1280.
10. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol. 1986;4(4):459-471.
11. Fisher B, Brown A, Wolmark N, et al. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer. 1990;66(2):220-227.
12. Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989;7(5):572-582.
13. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989;320(8):473-478.
14. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479-484.
15. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positivenode breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-1496.
16. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positivenode breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8(6):1005-1018.
17. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14(7):1982-1992.
18. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-1682.
19. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997;15(5):1858-1869.
20. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19(4):931-942.
21. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999;17(11):3374-3388.
22. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686-3696.
23. Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.
24. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
25. Ng'andu NH. An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox's model. Stat Med. 1997;16(6):611-626.
26. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. Statistics for Biology and Health; 2003.
27. Liang KY, Self SG, Liu XH. The Cox proportional hazards model with change point: an epidemiologic application. Biometrics. 1990;46(3):783-793.
28. Kaplan EL, Meier P. Nonparametric-Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-481.
29. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-2269.
30. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;52(1-3):227-237.
31. Bryant J, Fisher B, Gd N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 1998;51(3):239-253.
32. Jatoi I, Tsimelzon A, Weiss H, et al. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005;89:173-178.
33. Hess KR, Serachitopol DM, Brown BW. Hazard Function Estimators: A Simulation Study. Stat Med. 1999;18(2):3075-3088.
34. Putter H, Sasako M, Hartgrink HH, et al. Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial. Stat Med. 2005;24(18):2807-2821.
35. Lu J, Pajak TF. Statistical power for a long-term survival trial with a timedependent treatment effect. Controlled Clin Trials. 2000;21(6):561-573.
36. Lakatos E, Lan KKG. A comparison of sample size methods for the logrank statistic. Stat Med. 1992;11:179-191.
37. Royston P, Parmar MKB. An approach To trial design and analysis in the era of non-proportional hazards of the treatment effect. Trials. 2014;15:314.